NEW YORK - A Ludwig Cancer Research study has identified a key barrier to the efficacy of a promising combination of ...
News Medical on MSN4h
Ferroptosis contributes to immunosuppressionIron-dependent ferroptosis, a non-apoptotic cell death mechanism, is gaining attention for its role in immune suppression.
Immutep (ASX:IMM) has dosed the first patient in its pivotal Phase III trial evaluating eftilagimod alfa (efti) for the ...
SHANGHAI, China I March 23, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...
NANTONG, China and MELBOURNE, Australia I March 24, 2025 I Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA ...
The company said initial efficacy results from a Phase I trial did not provide a competitive benefit-risk profile in CLDN18.2-positive gastric and gastroesophageal cancer.
Technological advancements over the past few decades have unraveled the diversity and adaptability of tumors, shedding light ...
Synthetic Biology is advancing the use of microorganisms as cancer therapies, with scientists engineering bacteria to boost antitumor immunity and deliver ...
Discover how combining photodynamic therapy (PDT) with cisplatin enhances lung cancer treatment, promoting tumor cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback